Tagoor Laboratories Gets License to Produce ‘Favipiravir’ in India

Drug is being used to treat Covid-19 patients with mild to moderate risk

Hyderabad, October 4th, 2020 : [Press Release] Tagoor Laboratories Pvt. Ltd. has received Drugs Controller General of India license to manufacture Favipiravir. The Active Pharmaceutical Ingredients (API) of an Anti-Viral Drug approved by the DCGI for use in the treatment of Mild to moderate Covid-19 cases. The manufacturing facility located in West Godavari, Andhra Pradesh has successfully completed Favipiravir development and is planning to enhance its production capabilities.

The DCGI earlier approved the use of Favipiravir, an anti-viral drug used for treatment of influenza. The drug, developed in Japan is also used for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is a broad spectrum anti-viral agent and selectively inhibits RNA polymerase of influenza virus and prevents viral replication.

Commenting on the receiving the license, Dr. P. Kasi Viswanadha Raju, Managing Director said, “Tagoor Labs is capable of producing the drug without having to depend on any imports, as all the complex intermediates are developed in-house. Company aiming to manufacture Favipiravir in quantities sufficient to meet the growing domestic demand, which arose due to the pandemic. Additionally, Tagoor Labs also manufactures and supplies Hydroxychloroquine sulphate, also used to treat Covid -19 symptoms. Our manufacturing facility, approved by the WHO GMP, clocked annual turnover of Rs 270 cr in FY 2019-2020, and is expected to make a revenue of Rs 450 cr in FY 2020-2021. Company is having its R&D facility in Jeedimetla Industrial area, Hyderabad.”

Business Head Dr. Mohanbabu Maradolla said “Tagoor Laboratories Pvt. Ltd. is in talks with the top buyers in the domestic market and is also making collaborations with various Turkish, Iran, Egypt, and Russia partners to supply the Favipiravir API.”

About Tagoor Laborateries:

Tagoor Laborateries Pvt. Ltd. was established in 2005. Our Mentor and leader, Dr. P. V. Subramanyam Raju, have done a lot for our company and has shown us the path to unbelievable growth and success. It is the largest manufacturer of drug intermediates and have given an upgrade to all the chemical entities available in the market. We are the leading manufacturer, supplier and exporter of chemicals and our manufactured range includes Sesqui Hydrate, Omeprazole, Domperidone, Terbinafine HCL, etc. The Group has 2 firms, that are TAGOOR LABORATORIES PVT. LTD. and TAGOOR CHEMICALS PVT. LTD. in West Godavari (Andhra Pradesh, India). Both these Companies are backed with environmental friendly and upgraded machines, and also have cGMP standards. In addition to our existing business, now we are manufacturing Active Pharmaceutical Ingredients (APIs). All our machines and facilities are well established and with a total capacity of 500KL, it has more than 130 reactors whose range vary from 1KL  to15KL. Our main objective is to manufacture these APIs and its key intermediates that are of high competitive prices and also of supreme quality.

Exit mobile version